Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $238.6K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $238.6K.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $238.6K or moves back toward the trailing-twelve-month quarterly average of $59.65K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$238.6K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$238.6K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How CNTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
CNTA Competitors
Cost of Revenue for CNTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M USD+63.0%+84.1%43.0%
ZLABZai Lab LimitedLTM Jun 2026$195.71M USD+21.7%+37.2%43.5%
AAPGAscentage Pharma Group InternationalFY2025CN¥131.73M CNY+352.9%+81.6%23.6%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$109.99M USD+25.2%+56.7%16.4%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$12.47M USD-85.7%+576.6%202.2%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$611K USD-99.2%——
DYNDyne Therapeutics, Inc.LTM Jun 2026$521K USD———
APGEApogee Therapeutics, Inc.LTM Jun 2026$408K USD———
CNTACentessa Pharmaceuticals plcLTM Mar 2026$238.6K USD———
CELCCelcuity Inc.LTM Jun 2026$47K USD+33.3%——
Peer median (excluding CNTA) —+25.2%+81.6%43.0%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.